FIRST QUARTER IN BRIEF US Patent Office granted Active Biotech’s patent application for laquinimod in eye disorders (January 28) Active Biotech announced that the first patient was enrolled in the European clinical study of tasquinimod in myelofibrosis (February 24) Active Biotech announced that the first patient was dosed in the…
Daily treatment with laquinimod eye drops resulted in dose related and therapeutically relevant concentrations of laquinimod in both the anterior and posterior parts of the eye. Laquinimod eye drop treatment was safe and tolerable during 14 days’ administration Lund, May 5, 2025 – Active Biotech (NASDAQ STOCKHOLM: ACTI) today announced…
The shareholders of Active Biotech AB (publ), Reg. No. 556223-9227, with its registered office in Lund, Sweden, are invited to the Annual General Meeting of shareholders to be held on Wednesday, May 28, 2025 at 5 p.m. CEST in the premises of the Company at Scheelevägen 22, SE-223 63 Lund,…
Active Biotech (NASDAQ Stockholm:ACTI) announces today that the Annual Report 2024 now is available for download at www.activebiotech.com. The Annual Report will only be digitally distributed. “In the past year, we made significant progress in our clinical projects. For 2025, we will focus on advancing the ongoing clinical studies in…
Lund, Sweden, March 10, 2025 – Active Biotech (NASDAQ STOCKHOLM: ACTI) today announced the first patient has been dosed in the phase II clinical study of tasquinimod in myelofibrosis in the US. The clinical study, entitled Open Label Phase 2 Study of Tasquinimod in Patients with Primary Myelofibrosis, Post-Polycythemia Vera…
Lund Sweden, February 24, 2025 – Active Biotech (NASDAQ STOCKHOLM: ACTI) today announced that the first patient has been included in the phase Ib/II clinical study of tasquinimod in patients with myelofibrosis refractory or ineligible to JAK2 inhibitor treatment. “We are pleased to have enrolled the first patient into the…
EVENTS DURING THE FOURTH QUARTER European Patent Office granted Active Biotech’s patent application for eye drop formulation of laquinimod (October 23) Active Biotech’s clinical trial of tasquinimod in myelofibrosis was approved in Europe (October 30) Preclinical data of tasquinimod in myelofibrosis was presented at ASH 2024 (November 5) Active Biotech…
The number of shares and votes in Active Biotech AB (publ) has changed as a result of the recently completed rights issue. The 164,638,960 shares in relation to which allotment was conditional on that relevant FDI (Foreign Direct Investment) approvals from the Inspectorate of Strategic Products, have been registered in…
Lund, January 28, 2025, Active Biotech (NASDAQ STOCKHOLM: ACTI) today announced that the US Patent Office (USPTO) has granted Active Biotech’s US patent application 17/939,109 for laquinimod in eye disorders. “We continue our dedicated work with the laquinimod patent portfolio to optimize protection for its use in sight-threatening eye disorders…
The number of shares and votes in Active Biotech AB (publ) has changed as a result of the recently completed rights issue. Today, the last trading day of the month, there are in total 1,065,525,722 shares and votes in Active Biotech. An additional 164,638,960 shares issued in the rights issue…
In accordance with a decision made by the Annual General Meeting held on May 22, 2024, the Nomination Committee shall comprise the representatives for the three largest shareholders by votes, as per end of September 2024, and the Chairman of the Board. If a shareholder does not exercise its right…
Lund, December 9, 2024 – Active Biotech (NASDAQ STOCKHOLM: ACTI) today announced that preclinical data on tasquinimod, a small molecule immunomodulator in development for myelofibrosis are now available on the company’s website. The data were presented at the 66th American Society of Hematology Annual Meeting (ASH 2024) in San Diego,…
NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES OF AMERICA, AUSTRALIA, CANADA, NEW ZEALAND, HONG KONG, JAPAN, SWITZERLAND, SINGAPORE, SOUTH AFRICA, SOUTH KOREA, RUSSIA, BELARUS OR ANY OTHER JURISDICTION IN WHICH THE RELEASE, DISTRIBUTION OR PUBLICATION WOULD BE…
Lund, November 13, 2024, Active Biotech (NASDAQ STOCKHOLM: ACTI) today announced that the US Patent Office (USPTO) has issued a Notice of Allowance for Active Biotech’s patent application related to methods of treating eye diseases associated with excessive vascularization using laquinimod. The patent, which was filed under application no. 17/939,109,…
Lund, November 5, 2024 – Active Biotech (NASDAQ STOCKHOLM: ACTI) announced today that an abstract with preclinical data for tasquinimod in myelofibrosis has been accepted for presentation at the 66th American Society of Hematology Annual Meeting in San Diego, December 7-10, 2024 (ASH 2024). The abstract demonstrating efficacy of tasquinimod…
Lund, Sweden, October 30, 2024 – Active Biotech (NASDAQ STOCKHOLM: ACTI) today announced that the clinical phase I/II study of Tasquinimod in Patients with Myelofibrosis Refractory to or Intolerant for JAK2 Inhibition (HOVON 172 MF) has received full approval from the European Medicines Agency (EMA) and the Institutional Ethics Committees.…
NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES OF AMERICA, AUSTRALIA, CANADA, NEW ZEALAND, HONG KONG, JAPAN, SWITZERLAND, SINGAPORE, SOUTH AFRICA, SOUTH KOREA, RUSSIA, BELARUS OR ANY OTHER JURISDICTION IN WHICH THE RELEASE, DISTRIBUTION OR PUBLICATION WOULD BE…
The Extraordinary General Meeting of Active Biotech was held on October 23, 2024. The following main resolutions were passed. In accordance with the Board of Directors’ proposal, it was resolved to amend the Articles of Association, whereby the limits for the company’s share capital are changed to not less than…
Lund, October 23 2024 – Active Biotech (NASDAQ STOCKHOLM: ACTI) today announced that the European Patent Office (EPO) has granted Active Biotech’s patent application covering a proprietary developed eye drop formulation of laquinimod. The patent “Laquinimod formulation for ocular use”, published on October 23, 2024 under European patent number 4312986,…
THIRD QUARTER IN BRIEF Active Biotech entered agreement with MD Anderson for a clinical study of tasquinimod in myelofibrosis (July 1) Active Biotech provided an update on the clinical phase Ib/IIa study with tasquinimod in relapsed refractory multiple myeloma (July 15) Active Biotech reported intriguing intraocular concentrations achieved in a…
NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES OF AMERICA, AUSTRALIA, CANADA, NEW ZEALAND, HONG KONG, JAPAN, SWITZERLAND, SINGAPORE, SOUTH AFRICA, SOUTH KOREA, RUSSIA, BELARUS OR ANY OTHER JURISDICTION IN WHICH THE RELEASE, DISTRIBUTION OR PUBLICATION WOULD BE…
The shareholders of Active Biotech AB (publ), Reg. No. 556223-9227, with its registered office in Lund, Sweden, are invited to the Extraordinary General Meeting of shareholders to be held on Wednesday, October 23, 2024 at 11 a.m. CEST in the premises of the Company at Scheelevägen 22, SE-223 63 Lund,…
NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES OF AMERICA, AUSTRALIA, CANADA, NEW ZEALAND, HONG KONG, JAPAN, SWITZERLAND, SINGAPORE, SOUTH AFRICA, SOUTH KOREA, RUSSIA, BELARUS OR ANY OTHER JURISDICTION IN WHICH THE RELEASE, DISTRIBUTION OR PUBLICATION WOULD BE…
Lund, September 10 2024 – Active Biotech (NASDAQ STOCKHOLM: ACTI) today announced an update to the ongoing clinical phase I biodistribution study of laquinimod eye drops in patients undergoing vitrectomy. A proprietary formulation of laquinimod for corneal application was developed, taking the specific physico-chemical characteristics of this agent into account,…
SECOND QUARTER IN BRIEF Start of enrollment to the clinical phase I biodistribution study with laquinimod eye drops (April 3) Active Biotech acquired exclusive rights to patents of tasquinimod in combination therapy in multiple myeloma (May 22) Clinical activity and safety of naptumomab and docetaxel in non-small cell lung cancer…
Lund, July 15 2024 – Active Biotech (NASDAQ STOCKHOLM: ACTI) today announced an update to a clinical study of tasquinimod in patients with relapsed refractory multiple myeloma (RRMM) being conducted at the Abramson Cancer Center at the University of Pennsylvania in Philadelphia. The study is ongoing in its expansion cohort…
Lund, July 1, 2024 – Active Biotech (NASDAQ STOCKHOLM: ACTI) today announced it has entered into a clinical study agreement for a Phase II investigator-initiated clinical study investigating the use of tasquinimod in myelofibrosis. The study will be led by Lucia Masarova, M.D., assistant professor of Leukemia at The University…
The number of shares and votes in Active Biotech has changed as a result of allotment of performance shares under the company’s incentive program for the company’s employees (Plan 2020/2024). Today, the last trading day of the month, there are in total 361,813,142 shares and votes in Active Biotech. For…
Lund, May 28, 2024 – Active Biotech (NASDAQ STOCKHOLM: ACTI) announces today that NeoTX Therapeutics, exclusive licensee of naptumomab estafenatox (naptumomab, NAP) from Active Biotech, will present initial results from phase IIa trial with NAP and docetaxel in advanced/metastatic Non-Small Cell Lung Cancer (NSCLC) patients, at the American Society of…
The Annual General Meeting of Active Biotech was held on May 22, 2024. The following main resolutions were passed.In accordance with the Board of Directors’ proposal, it was resolved that no dividend would be paid for the financial year 2023, and that the Company’s accumulated loss shall be carried forward.…
Lund, May 22, 2024 – Active Biotech (NASDAQ STOCKHOLM: ACTI) today announces it has entered into an exclusive license agreement with the Wistar Institute of Anatomy and Biology (“Wistar”), Philadelphia, US for the global rights to Wistars interest in the joint IP relating to the use of tasquinimod in combination…
FIRST QUARTER IN BRIEF Preparations ongoing for start of the clinical proof of concept studies with tasquinimod in myelofibrosis The expansion cohort of the study in multiple myeloma is ongoing according to plan EVENTS AFTER THE END OF THE PERIOD Start of enrollment to the clinical phase I biodistribution study…
The shareholders of Active Biotech AB (publ), Reg. No. 556223-9227, with its registered office in Lund, Sweden, are invited to the Annual General Meeting of shareholders to be held on Wednesday, May 22, 2024 at 5 p.m. CEST in the premises of the Company at Scheelevägen 22, SE-223 63 Lund,…
Active Biotech (NASDAQ Stockholm:ACTI) announces today that the Annual Report 2023 now is available for download at www.activebiotech.com. The Annual Report will only be digitally distributed. “I am very pleased with the progress of our projects in 2023. We are strengthened in our belief that our projects have the potential to…
Lund, April 3, 2024 – Active Biotech (NASDAQ STOCKHOLM: ACTI) today announced that the clinical phase I biodistribution study Safety, Tolerability, and Distribution of Laquinimod Eye Drops: The LION Study (clinicaltrials.gov NCT06161415) with laquinimod eye drops is now recruiting patients following the approval from the Food and Drug Administration (FDA)…
FOURTH QUARTER IN BRIEF Lead Principal Investigator Rebekka Schneider-Kramann presents the clinical plan and positioning of tasquinimod in myelofibrosis (December 1) Active Biotech enters into collaboration agreement for clinical ocular biodistribution study with laquinimod (December 5) Active Biotech announces outcome of the Company’s rights issue (December 6) Preclinical data of…
The number of shares and votes in Active Biotech AB (publ) has changed as a result of the recently completed rights issue. Today, the last trading day of the month, there are in total 361,739,047 shares and votes in Active Biotech. For further information, please contact: Helén Tuvesson, CEO, +46 46…
Lund, December 22, 2023 – Active Biotech (NASDAQ STOCKHOLM: ACTI) today announced an update to the timelines of its scheduled clinical studies to be initiated in 2024, backed by the company’s recently completed successful financing round. The next step in the development of the drug candidate laquinimod will be a…
Lund, December 14, 2023 – Active Biotech (NASDAQ STOCKHOLM: ACTI) today announced that preclinical data on tasquinimod, a small molecule immunomodulator, in myelofibrosis and myelodysplastic syndrome (MDS) are now available on the company’s website. The data were presented at the 65th American Society of Hematology Annual Meeting (ASH 2023) in…
NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES OF AMERICA, AUSTRALIA, CANADA, NEW ZEALAND, HONG KONG, JAPAN, SWITZERLAND, SINGAPORE, SOUTH AFRICA, SOUTH KOREA, RUSSIA, BELARUS OR ANY OTHER JURISDICTION IN WHICH THE RELEASE, DISTRIBUTION OR PUBLICATION WOULD BE…
Lund, December 5, 2023 – Active Biotech (NASDAQ STOCKHOLM: ACTI) today announced that it has entered into a clinical trial collaboration agreement with the Global Ophthalmic Research Center (GORC), Los Altos, CA, US for a phase I clinical ocular biodistribution study with laquinimod eye drops. GORC is the study administrative…
In accordance with a decision made by the Annual General Meeting held on May 24, 2023, the Nomination Committee shall comprise the representatives for the three largest shareholders by votes, as per end of September 2023, and the Chairman of the Board. If a shareholder does not exercise its right…
Lund, December 1, 2023 – Active Biotech (NASDAQ STOCKHOLM: ACTI) announced today that a recorded presentation and an interview on the positioning of tasquinimod in the evolving landscape of myelofibrosis with Professor Rebekka Schneider-Kramann are available on the company website (www.activebiotech.com). Active Biotech has communicated earlier that it will focus…
NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES OF AMERICA, AUSTRALIA, CANADA, NEW ZEALAND, HONG KONG, JAPAN, SWITZERLAND, SINGAPORE, SOUTH AFRICA, SOUTH KOREA, RUSSIA, BELARUS OR ANY OTHER JURISDICTION IN WHICH THE RELEASE, DISTRIBUTION OR PUBLICATION WOULD BE…
NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES OF AMERICA, AUSTRALIA, CANADA, NEW ZEALAND, HONG KONG, JAPAN, SWITZERLAND, SINGAPORE, SOUTH AFRICA, SOUTH KOREA, RUSSIA, BELARUS OR ANY OTHER JURISDICTION IN WHICH THE RELEASE, DISTRIBUTION OR PUBLICATION WOULD BE…
NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES OF AMERICA, AUSTRALIA, CANADA, NEW ZEALAND, HONG KONG, JAPAN, SWITZERLAND, SINGAPORE, SOUTH AFRICA, SOUTH KOREA, RUSSIA, BELARUS OR ANY OTHER JURISDICTION IN WHICH THE RELEASE, DISTRIBUTION OR PUBLICATION WOULD BE…
THIRD QUARTER IN BRIEF Collaboration agreement for clinical study with tasquinimod in myelofibrosis signed (July 31) Tasquinimod successfully completed dose optimization in patients with multiple myeloma and advances into the pre-planned expansion cohort (September 11) Clinical safety and preclinical ocular biodistribution for laquinimod eye drops presented at the IOIS meeting…
Lund, November 2, 2023 – Active Biotech (NASDAQ STOCKHOLM: ACTI) announced today that two abstracts with preclinical data for tasquinimod in myelofibrosis and myelodysplastic syndrome have been accepted for presentation at the 65th American Society of Hematology Annual Meeting in San Diego, December 9-12, 2023 (ASH 2023). The abstract demonstrating…
Lund, September 13 2023 – Active Biotech (NASDAQ Stockholm:ACTI) announces today that data from the recently completed phase I study with the eye drop formulation of laquinimod, a small molecule immunomodulator in development for non-infectious uveitis, together with results from the intraocular biodistribution study of laquinimod eye drops in rabbit,…
Lund Sweden, September 11, 2023 – Active Biotech (NASDAQ STOCKHOLM: ACTI) today announces the successful completion of the dose escalation of tasquinimod in combination with the orally administered antimyeloma agents ixazomib, lenalidomide, and dexamethasone (IRd) in patients with relapsed or refractory multiple myeloma. 6 patients have been treated with increasing…
